Q3 2023 · 13F-HR
Octagon Capital Advisors LPholdings as filed
Filed 2023-11-14 · accession 0001214659-23-015129
$650.9M
Reported value
40
Positions
2023-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $119.1M | 18.3% | 3,130,000 | Common | SOLE |
| G76279101 | ROIV | ROIVANT SCIENCES LTD | $51.0M | 7.84% | 4,367,000 | Common | SOLE |
| 23257D103 | CBAYUSD | CYMABAY THERAPEUTICS INC | $45.8M | 7.04% | 3,073,750 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $38.6M | 5.93% | 2,369,000 | Common | SOLE |
| 45258J102 | IMVT | IMMUNOVANT INC | $38.4M | 5.90% | 1,000,000 | PUT | SOLE |
| 03969F109 | RCUS | ARCUS BIOSCIENCES INC | $35.3M | 5.43% | 1,968,000 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $32.4M | 4.98% | 1,284,000 | Common | SOLE |
| 60468T105 | MRTXEUR | MIRATI THERAPEUTICS INC | $28.5M | 4.38% | 655,051 | Common | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $25.7M | 3.94% | 675,000 | PUT | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $25.6M | 3.94% | 971,639 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $20.9M | 3.21% | 759,898 | Common | SOLE |
| 282559103 | ETNBGBP | 89BIO INC | $18.8M | 2.89% | 1,219,157 | Common | SOLE |
| 75974E103 | — | RENEO PHARMACEUTICALS INC | $17.4M | 2.67% | 2,279,870 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $16.4M | 2.51% | 1,067,143 | Common | SOLE |
| 03753U106 | APLSUSD | APELLIS PHARMACEUTICALS INC | $15.2M | 2.34% | 400,000 | CALL | SOLE |
| 037326105 | ANTX | AN2 THERAPEUTICS INC | $14.0M | 2.14% | 867,575 | Common | SOLE |
| 03237H101 | AMLX | AMYLYX PHARMACEUTICALS INC | $12.7M | 1.96% | 695,000 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $8.8M | 1.35% | 2,777,778 | Common | SOLE |
| 02083G100 | NVLSEUR | ALPINE IMMUNE SCIENCES INC | $8.6M | 1.32% | 750,000 | Common | SOLE |
| 38341P102 | GOSS | GOSSAMER BIO INC | $6.8M | 1.05% | 8,187,883 | Common | SOLE |
| 008064107 | — | AEROVATE THERAPEUTICS INC | $6.7M | 1.04% | 497,370 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $6.6M | 1.01% | 480,000 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $6.2M | 0.95% | 692,945 | Common | SOLE |
| 69353Y103 | PMVP | PMV PHARMACEUTICALS INC | $5.6M | 0.85% | 904,000 | Common | SOLE |
| 45790W108 | — | INOZYME PHARMA INC | $5.5M | 0.84% | 1,300,000 | Common | SOLE |
| 98422T100 | — | XILIO THERAPEUTICS INC | $4.9M | 0.75% | 2,318,500 | Common | SOLE |
| 03589W102 | ANNX | ANNEXON INC | $4.8M | 0.74% | 2,050,000 | Common | SOLE |
| 38000Q102 | GLYCEUR | GLYCOMIMETICS INC | $4.5M | 0.69% | 3,000,000 | Common | SOLE |
| 92686J106 | VKTX | VIKING THERAPEUTICS INC | $4.2M | 0.64% | 375,000 | Common | SOLE |
| 61225M102 | GLUE | MONTE ROSA THERAPEUTICS INC | $3.9M | 0.60% | 812,895 | Common | SOLE |
| 471871103 | — | JASPER THERAPEUTICS INC | $3.1M | 0.48% | 4,468,114 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $3.1M | 0.47% | 475,600 | Common | SOLE |
| 92764N102 | VIR | VIR BIOTECHNOLOGY INC | $3.0M | 0.47% | 325,050 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $2.7M | 0.41% | 300,000 | CALL | SOLE |
| 528872302 | LXRX | LEXICON PHARMACEUTICALS INC | $2.1M | 0.32% | 1,923,076 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $1.2M | 0.19% | 204,500 | Common | SOLE |
| 46565G104 | 5E7 | ITEOS THERAPEUTICS INC | $1.1M | 0.17% | 102,000 | Common | SOLE |
| 23257D103 | CBAYUSD | CYMABAY THERAPEUTICS INC | $894,600 | 0.14% | 60,000 | PUT | SOLE |
| 09063M205 | BNOXN | BIONOMICS LIMITED | $453,600 | 0.07% | 168,000 | Common | SOLE |
| 426897302 | CTRVGBP | HEPION PHARMACEUTICALS INC | $336,825 | 0.05% | 67,500 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.